Search research articles
Contact Us
Filters
Showing results (461-470 of 573) with videos related to
Page
of 58
Sort By:
American Heart Journal
|
March 11, 2025
Rationale and design of the ILIAS ANOCA clinical trial: A blinded-arm controlled trial for routine ad-hoc coronary function testing
Coen K M Boerhout, Hanae F Namba, Tommy Liu, et al.
Circulation. Cardiovascular Interventions
|
June 10, 2015
Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry
Usman Baber, Roxana Mehran, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions
|
January 31, 2021
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES
Katherine H Chau, Ajay J Kirtane, Rachel M Easterwood, et al.
American Heart Journal
|
June 5, 2017
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study
Usman Baber, Samantha Sartori, Melissa Aquino, et al.
Journal of the American College of Cardiology
|
August 29, 2015
Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention
Philippe Généreux, Gennaro Giustino, Bernhard Witzenbichler, et al.
Transfusion
|
February 11, 2012
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study
Sara Richman, Adrian P Gee, David H McKenna, et al.
Circulation
|
October 13, 2021
Systems of Care for ST-Segment-Elevation Myocardial Infarction: A Policy Statement From the American Heart Association
Alice K Jacobs, Murtuza J Ali, Patricia J Best, et al.
Circulation. Cardiovascular Interventions
|
October 14, 2015
Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study
Giora Weisz, Nathaniel R Smilowitz, Ajay J Kirtane, et al.
The Canadian Journal of Cardiology
|
January 29, 2026
Defining Population at Risk and Assessment of Patients with Presumed Coronary Microvascular and Vasomotor Dysfunction
Laurie-Anne Boivin-Proulx, Erick Schampaert, Kevin Bainey, et al.
Circulation. Cardiovascular Interventions
|
December 21, 2018
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents
Akiko Maehara, Gary S Mintz, Bernhard Witzenbichler, et al.
Page
of 58
Search research articles
Search
Showing results (461-470 of 573) with videos related to
Sort By:
Page
of 58
American Heart Journal
|
March 11, 2025
Rationale and design of the ILIAS ANOCA clinical trial: A blinded-arm controlled trial for routine ad-hoc coronary function testing
Coen K M Boerhout, Hanae F Namba, Tommy Liu, et al.
Circulation. Cardiovascular Interventions
|
June 10, 2015
Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry
Usman Baber, Roxana Mehran, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions
|
January 31, 2021
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES
Katherine H Chau, Ajay J Kirtane, Rachel M Easterwood, et al.
American Heart Journal
|
June 5, 2017
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study
Usman Baber, Samantha Sartori, Melissa Aquino, et al.
Journal of the American College of Cardiology
|
August 29, 2015
Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention
Philippe Généreux, Gennaro Giustino, Bernhard Witzenbichler, et al.
Transfusion
|
February 11, 2012
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study
Sara Richman, Adrian P Gee, David H McKenna, et al.
Circulation
|
October 13, 2021
Systems of Care for ST-Segment-Elevation Myocardial Infarction: A Policy Statement From the American Heart Association
Alice K Jacobs, Murtuza J Ali, Patricia J Best, et al.
Circulation. Cardiovascular Interventions
|
October 14, 2015
Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study
Giora Weisz, Nathaniel R Smilowitz, Ajay J Kirtane, et al.
The Canadian Journal of Cardiology
|
January 29, 2026
Defining Population at Risk and Assessment of Patients with Presumed Coronary Microvascular and Vasomotor Dysfunction
Laurie-Anne Boivin-Proulx, Erick Schampaert, Kevin Bainey, et al.
Circulation. Cardiovascular Interventions
|
December 21, 2018
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents
Akiko Maehara, Gary S Mintz, Bernhard Witzenbichler, et al.
Page
of 58